Astrazeneca Pharma India Ltd

- No specific mention of any current or future fundraising through debt or equity in the provided AGM transcript. - The company currently operates as a zero-debt entity (Page 17). - There is a focus on managing expenses and growth internally without reference to new capital raising. - The management acknowledges ongoing investments for growth but does not indicate plans for raising new equity or debt. - Dividend payments are ongoing, with an increase mentioned, implying cash flow strength. - Management remains cautious about forward-looking financial commitments and emphasizes prudent asset and financial management. In summary, there is no announced or planned fundraising through debt or equity as per the information on Page 25 and related sections.

The document does not explicitly mention the current or expected order book or pending orders for AstraZeneca Pharma India Limited. However, some relevant points related to business and growth expectations include: - The company is focusing on revenue growth and improving patient access. - Recent launches and collaborations are expected to enhance market presence, especially in oncology and rare diseases. - The company is evaluating new business models to reach diverse markets. - Management is cautious about making forward-looking statements but expects growth in India’s contribution to AstraZeneca’s global targets by 2030. - Cost savings from plant closure and ongoing pipeline assessment could impact future operations positively. - Deferred revenue pertains to the Mankind Pharma arrangement from this year onward. No specific figures or details on order book/pending orders are provided in the transcript.

From the provided transcript on page 24 (August 08, 2024): - The company is focusing on revenue growth and improving access to patients, which may imply ongoing investments in innovative medicines and collaborations. - There was mention of cost savings related to the closure of a plant, indicating strategic operational changes. - Management is actively ensuring the right process for valuable assets like land. - No specific figures or detailed plans for current or future capital expenditure or strategic investment were disclosed. - The company is becoming a specialist organization focusing more on trading products, possibly redirecting investments accordingly. Summary: While no explicit capex or strategic investment figures were provided, AstraZeneca Pharma India is focusing on growth through innovative product launches, collaborations, operational efficiency (including plant closure), and asset management to support future expansion.